Brazil's Diagnostic Medicine Market - Its Growth and Profits - 2 views
-
After nearly three years on the market, Alliar – the diagnostic medicine group – continues with its aggressive expansion strategy with a total of 65 diagnostic imaging units in Brazil and reaching revenues of about R$310 million (US$125 million) and a 40 % average growth
-
Alliar’s president has stated that “It’s a segment that has differentiated growth possibilities, more accelerated than healthcare in general”. “The sector is still very fragmented and therefore opportunities for consolidation still exist.”
- ...11 more annotations...
-
Since the beginning Alliar has been taking advantage of the current Brazilian market forces that have health insurance companies setting up low prices for this particular line of services with significant detriment to its profit margins and a growing middle class expansion that have substantially increased its demand for medical diagnostic services.
-
Fleury SA (FLRY3) and Diagnosticos of America SA (DASA), Brazil’s biggest publicly traded diagnostics companies are Alliar strongest competitors, however, these are services in the major centers such as São Paulo and Rio de Janeiro. Thus, Alliar has focused in smaller cities having most of its units in São Paulo and Minas Gerais away from their metropolitan areas, areas that are not fully served by FLRY3 and DASA.
-
In 2010, a partnership between the Blackstone Group (NYSE: BX) and Patria Investments – Brazil’s leading private equity fund firm – was established allowing Blackstone to buy a 40% stake in Patria Investments with the goal of building their businesses in Brazil and throughout South America.
-
-
-
-
-
-
-
-
-
http://www.businessoffashion.com/2014/02/brazil-fast-fashion-heats.html This other article describes how fashion businesses are trying to get into Brazil and take advantage of its strong economy.
-